エルトロンボパグ オラミン
エルトロンボパグ オラミン 物理性質
- 貯蔵温度 :
- under inert gas (nitrogen or Argon) at 2–8 °C
- 溶解性:
- DMSO:56.33(Max Conc. mg/mL);99.76(Max Conc. mM)
DMF:1.0(Max Conc. mg/mL);1.77(Max Conc. mM)
DMF:PBS (pH 7.2) (1:3):0.25(Max Conc. mg/mL);0.44(Max Conc. mM)
Ethanol:0.1(Max Conc. mg/mL);0.18(Max Conc. mM)
- 外見 :
- Powder
- 安定性：:
- Hygroscopic
- InChIKey:
- LQQUHOUXABUDJA-OUFJFOJPSA-N
- SMILES:
- C(N)CO.O=C1/C(/C(C)=NN1C1C=CC(C)=C(C)C=1)=N\NC1C=CC=C(C2C=CC=C(C(=O)O)C=2)C=1O
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
| 絵表示（GHS） |
|
| 注意喚起語 |
|
| 危険有害性情報 |
| コード |
危険有害性情報 |
危険有害性クラス |
区分 |
注意喚起語 |
シンボル |
P コード |
| H319 |
強い眼刺激 |
眼に対する重篤な損傷性/眼刺激 性 |
2A |
警告 |
|
P264, P280, P305+P351+P338,P337+P313P |
| H412 |
長期的影響により水生生物に有害 |
水生環境有害性、慢性毒性 |
3 |
|
|
P273, P501 |
|
| 注意書き |
| P264 |
取扱い後は皮膚をよく洗うこと。 |
| P264 |
取扱い後は手や顔をよく洗うこと。 |
| P273 |
環境への放出を避けること。 |
| P280 |
保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。 |
| P305+P351+P338 |
眼に入った場合：水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。 |
| P501 |
内容物/容器を．．．に廃棄すること。 |
|
エルトロンボパグ オラミン 価格
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
エルトロンボパグ オラミン 化学特性,用途語,生産方法
効能
血小板減少症治療薬, トロンボポエチン受容体作動薬
商品名
レボレード (ノバルティスファーマ)
説明
Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough.Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.
使用
Treatment of chemotherapy-induced thrombocytopenia and treatment of immune thrombocytopenic purpura.
臨床応用
Eltrombopag olamine, a thrombopoietin receptor (TpoR) agonist,
was approved in late 2008 for the once-daily, oral short-term and long-term treatment of adult patients with previously treated
chronic idiopathic thrombocytopenic purpura (ITP). It is the first
small-molecule TpoR agonist and was launched in the U.S. for this
indication in 2009 by GlaxoSmithKline (GSK). Because eltrombopag
is a small molecule, the drug is administered orally and has
a reduced potential for causing an immune system reaction
versus alternative protein-based therapies. In 2010, eltrombopag
was approved in Europe for the long-term treatment of adult
patients with previously treated chronic ITP.
合成
The synthesis began
with the nitration of 2-bromophenol (39) with sodium nitrate
and sulfuric acid in water at 10??C to give 2-bromo-6-nitrophenol
(40) in 25% yield, which was methylated using methyl iodide and
potassium carbonate in refluxing acetone providing 2-bromo-
6-nitroanisole (41) in 76% yield (the Scheme).40 Suzuki coupling of
compound 41 with 3-carboxyphenyl boronic acid with Pd(PPh3)4
and 2 M sodium carbonate in refluxing dioxane gave 20-methoxy-
30-nitrobiphenyl-3-carboxylic acid (42) in 47% yield as a tan
powder. Demethylation using 48% HBr (aq) in refluxing acetic acid
resulted in a 79% yield of 20-hydroxy-30-nitrobiphenyl-3-carboxylic
acid (43). The nitro group of compound 43 was reduced via catalytic
hydrogenation at 50 psi at room temperature over Pd/C in
mixed ethanol/3 M aq NaOH solution to give 30-amino-20-hydroxybiphenyl-
3-carboxylic acid (44) in quantitative yield. The
intermediate 1-(3,4-dimethylphenyl)-3-methyl-2,5-dihydro-1Hpyrazol-
5-one (47) was prepared by condensing of 3,4-dimethylphenyl-
hydrazine 45 with ethyl acetoacetate 46 with sodium
acetate in refluxing acetic acid in 76% yield. Treatment of (44) with
sodium nitrite in 1 M HCl at 5??C, followed by condensation with
1-(3,4-dimethylphenyl)-3-methyl-2,5-dihydro-1H-pyrazol-5-one
(47) at a constant pH of 7¨C8 via the addition of sodium bicarbonate
and ethanol afforded eltrombopag in 32% yield. Finally, eltrombopag
was treated with hydroxyl ethylamine to give eltrombopag
olamine (VIII).
エルトロンボパグ オラミン 上流と下流の製品情報
原材料
準備製品
エルトロンボパグ オラミン 生産企業
Global( 318)Suppliers
エルトロンボパグ オラミン スペクトルデータ(1HNMR)
496775-62-3(エルトロンボパグ オラミン)キーワード:
- 496775-62-3
- Sb 497115gr
- Unii-4U07F515lg
- 3'-[(2Z)-2-[1-(3,4-DiMethylphenyl)-1,5-dihydro-3-Methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid coMpd. with 2-aMinoethanol(1:2)
- EltroMbopag diethanolaMine salt
- EltroMbopag IMpurity
- 2-aminoethanol with (Z)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylate (2:1)
- Unii-4U07F515
- 2-aminoethanol,3-[(5E)-5-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]hydrazinylidene]-6-oxocyclohexa-1,3-dien-1-yl]benzoic acid
- 2-Aminoethanol (E)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydra
- ELTROMBOPAG OLAMINE IH
- 3'-[(2Z)-2-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid compd. with 2-aminoethanol
- Revolade
- ELTROMBOPAG OL
- ELTROMBOPAG DIETHANOLAMINE SALT; PROMACTA; REVOLADE; SB-497115GR
- 2-aminoethanol (Z)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylate
- Eltrombopag Olamin
- Eltrombopag ethanolamine
- Promacta Olamine
- 2-aminoethanolhemi((Z)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylate)
- 2-aminoethanol,3-[(5E)-5-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]hydrazinylidene]-6-oxocyclohexa-1,3-dien-1-yl]benzoicaci
- Unii-4U07F515lg ISO 9001：2015 REACH
- Eltrombopag Olamine (SB-497115GR)
- ltrombopag Impurity 13
- Eltrombopag OlamineQ: What is
Eltrombopag Olamine Q: What is the CAS Number of
Eltrombopag Olamine Q: What are the applications of
Eltrombopag Olamine
- Eltrombopag olamine
- EltroMbopag OlaMine API
- Eltrombopag Diolamine
- 8-Benzothiazolecarboxaldehyde
- 2-Aminoethan-1-ol hemi((Z)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylate)
- 496775-62-3
- エルトロンボパグ オラミン
- エルトロンボパグ オラミン (JAN)